Claims:

[Claim 1]. A WWP2 inhibitor for use in a method of treating or preventing fibrosis.

[Claim 2]. Use of a WWP2 inhibitor in the manufacture of a medicament for use in a method of treating or preventing fibrosis.

[Claim 3]. The WWP2 inhibitor for use according to claim 1 or the use according to claim 2, wherein the fibrosis is of the heart, kidney, liver, lung, skeletal muscle, blood vessels, eye, skin, pancreas, bowel, small intestine, large intestine, colon, brain, and/or bone marrow.

[Claim 4]. A WWP2 inhibitor for use in a method of treating or preventing pathological inflammation.

[Claim 5]. Use of a WWP2 inhibitor in the manufacture of a medicament for use in a method of treating or pathological inflammation.

[Claim 6]. The WWP2 inhibitor for use according to claim 5 or the use according to claim 5, wherein the pathological inflammation is associated with a chronic infection, a cancer, an autoimmune disease, a degenerative disease or an allergic disease.

[Claim 7]. The WWP2 inhibitor for use or the use according to any one of claims 1 to 6, wherein the WWP2 inhibitor is an inhibitor of a WWP2 isoform comprising the C2 domain, optionally wherein the WWP2 inhibitor is an inhibitor of WWP2-FL and/or WWP2-N.

[Claim 8]. The WWP inhibitor for use or the use according to any one of claims 1 to 7, wherein the WWP2 inhibitor is a WWP2-binding molecule, a WWP2 target-binding molecule, or a molecule capable of reducing expression of WWP2.

[Claim 9]. The WWP inhibitor for use or the use according to any one of claims 1 to 8, wherein the WWP2 inhibitor is a small molecule.

[Claim 10]. The WWP inhibitor for use or the use according to any one of claims 1 to 9, wherein the method comprises administering the agent to a subject in which expression and/or activity of WWP2 is upregulated.